Lynparza was approved in 2020 as a second-line therapy for homologous recombination repair (HRR) gene-mutated mCRPC last year, but extending its label to include non-HRR patients in the frontline ...
Also approved to treat ovarian, prostate and pancreatic cancer, Lynparza brought in $2.75 billion in sales for AZ last year, a rise of around 25%, while Merck booked just under $1 billion from the ...
Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients. In December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results